TDP-43 proteinopathies: Pathological identification of brain regions differentiating clinical phenotypes

Brain

Volumn 138, Issue 10, 2015, Pages 3110-3122

  Tan, Rachel H ^a,b   Kril, Jillian J ^c   Fatima, Manaal ^a,b,c   McGeachie, Andrew ^a,b   McCann, Heather ^a   Shepherd, Claire ^a,b   Forrest, Shelley L ^c   Affleck, Andrew ^a,b   Kwok, John B J ^a,b   Hodges, John R ^a,b,d   Kiernan, Matthew C ^c   Halliday, Glenda M ^a,b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ARC CENTRE OF EXCELLENCE IN COGNITION AND ITS DISORDERS   (Australia)

Author keywords

Alzheimer's disease; amyotrophic lateral sclerosis; behavioural variant frontotemporal dementia; TDP 43 proteinopathies

Indexed keywords

TAR DNA BINDING PROTEIN; DNA BINDING PROTEIN; TDP-43 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTERIOR CINGULATE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; GENETIC ANALYSIS; HIPPOCAMPAL SCLEROSIS; HUMAN; HYPOGLOSSAL NUCLEUS; MALE; PHENOTYPE; PRIORITY JOURNAL; TDP 43 PROTEINOPATHY; BRAIN; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TDP-43 PROTEINOPATHIES;

EID: 84952884263     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv220     Document Type: Article

References (56)

1. Amador-Ortiz C, Ahmed Z, Zehr C, Dickson DW. Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol 2007; 113: 245-52.
2. Bak TH, Hodges JR. Motor neurone disease, dementia and aphasia: coincidence, co-occurrence or continuum? J Neurol 2001; 248: 260-70.
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
4. Brambati SM, Renda NC, Rankin KP, Rosen HJ, Seeley WW, Ashburner J, et al. A tensor based morphometry study of longitudinal gray matter contraction in FTD. Neuroimage 2007; 35: 998-1003.
5. Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 2014; 127: 423-39.
6. Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20-38.
7. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-9.
8. Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain 2011; 134: 2582-94.
9. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007; 114: 5-22.
10. Chen Z, Ma L. Grey matter volume changes over the whole brain in amyotrophic lateral sclerosis: a voxel-wise meta-analysis of voxel based morphometry studies. Amyotroph Lateral Scler 2010; 11: 549-54.
11. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-56.
12. Dickson DW, Josephs KA, Amador-Ortiz C. TDP-43 in differential diagnosis of motor neuron disorders. Acta Neuropathol 2007; 114: 71-9.
13. Dobson-Stone C, Hallupp M, Loy CT, Thompson EM, Haan E, Sue CM, et al. C9ORF72 repeat expansion in Australian and Spanish frontotemporal dementia patients. PLoS One 2013; 8: e56899.
14. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimers disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-29.
15. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971; 76: 378-82.
16. Geser F, Lee VM, Trojanowski JQ. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology 2010; 30: 103-12.
17. Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 2013; 12: 368-80.
18. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011; 7: 639-49.
19. Herman AM, Khandelwal PJ, Stanczyk BB, Rebeck GW, Moussa CEH. beta-Amyloid triggers ALS-associated TDP-43 pathology in AD models. Brain Res 2011; 1386: 191-9.
20. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimers Association guidelines for the neuropathologic assessment of Alzheimers disease. Alzheimers Dement 2012; 8: 1-13.
21. Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, et al. Staging TDP-43 pathology in Alzheimers disease. Acta Neuropathol 2014a; 127: 441-50.
22. Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, Baker M, et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 2008; 70: 1850-7.
23. Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimers disease. Acta Neuropathol 2014b; 127: 811-24.
24. Jung Y, Dickson DW, Murray ME, Whitwell JL, Knopman DS, Boeve BF, et al. TDP-43 in Alzheimers disease is not associated with clinical FTLD or Parkinsonism. J Neurol 2014; 261: 1344-8.
25. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet 2011; 377: 942-55.
26. King A, Sweeney F, Bodi I, Troakes C, Maekawa S, Al-Sarraj S. Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimers disease. Neuropathology 2010; 30: 408-19.
27. Kobayashi Z, Tsuchiya K, Arai T, Yokota O, Yoshida M, Shimomura Y, et al. Clinicopathological characteristics of FTLD-TDP showing corticospinal tract degeneration but lacking lower motor neuron loss. J Neurol Sci 2010; 298: 70-7.
28. Kosaka T, Fu YJ, Shiga A, Ishidaira H, Tan CF, Tani T, et al. Primary lateral sclerosis: Upper-motor-predominant amyotrophic lateral sclerosis with frontotemporal lobar degeneration-immunohistochemical and biochemical analyses of TDP-43. Neuropathology 2012; 32: 373-84.
29. Kwok JB, Taddei K, Hallupp M, Fisher C, Brooks WS, Broe GA, et al. Two novel (M233T and R278T) presenilin-1 mutations in earlyonset al.zheimers disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport 1997; 8: 1537-42.
30. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
31. Lillo P, Mioshi E, Burrell JR, Kiernan MC, Hodges JR, Hornberger M. Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One 2012; 7: e43993.
32. Lomen-Hoerth C. Clinical phenomenology and neuroimaging correlates in ALS-FTD. J Mol Neurosci 2011; 45: 656-62.
33. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59: 1077-9.
34. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111-3.
35. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010; 119: 1-4.
36. Mackenzie IRA, Feldman HH. Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J Neuropath Exp Neurol 2005; 64: 730-9.
37. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Picks Disease. Arch Neurol 2001; 58: 1803-9.
38. Mioshi E, Hsieh S, Caga J, Ramsey E, Chen K, Lillo P, et al. A novel tool to detect behavioural symptoms in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15: 298-304.
39. Mirra SS, Heyman A, McKeel D, Sumi SM, Brain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimers Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimers disease. Neurology 1991; 41: 479-86.
40. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimers Association guidelines for the neuropathologic assessment of Alzheimers disease: a practical approach. Acta Neuropathol 2012; 123: 1-11.
41. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997; 9 (Suppl 1): 173-6.
42. Muresan V, Villegas C, Ladescu Muresan Z. Functional interaction between amyloid-beta precursor protein and peripherin neurofilaments: a shared pathway leading to Alzheimers disease and Amyotrophic Lateral Sclerosis? Neurodegener Dis 2014; 13: 122-5.
43. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-54.
44. Nelson PT, Schmitt FA, Lin YS, Abner EL, Jicha GA, Patel E, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 2011; 134: 1506-18.
45. Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2012; 83: 102-8.
46. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-77.
47. Rosen HJ, Gorno-Tempini ML, Goldman WP, Perry RJ, Schuff N, Weiner M, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002; 58: 198-208.
48. Schofield EC, Halliday GM, Kwok J, Loy C, Double KL, Hodges JR. Low serum progranulin predicts the presence of mutations: a prospective study. J Alzheimers Dis 2010; 22: 981-4.
49. Seeley WW, Carlin DA, Allman JM, Macedo MN, Bush C, Miller BL, et al. Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol 2006; 60: 660-7.
50. Strong MJ, Lomen-Hoerth C, Caselli RJ, Bigio EH, Yang W. Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Ann Neurol 2003; 54 (Suppl 5): S20-3.
51. Tan RH, Shepherd CE, Kril JJ, McCann H, McGeachie A, McGinley C, et al. Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol Commun 2013; 1: 33.
52. Tremblay C, St-Amour I, Schneider J, Bennett DA, Calon F. Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropath Exp Neurol 2011; 70: 788-98.
53. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, et al. Concomitant TAR-DNA-binding in Alzheimer disease and protein 43 pathology is present corticobasal degeneration but not in other tauopathies. J Neuropath Exp Neurol 2008; 67: 555-64.
54. Vatsavayi AVV, Kofler J, DeMichele-Sweet MAA, Murray PS, Lopez OL, Sweet RA. TAR DNA-binding protein 43 pathology in Alzheimers disease with psychosis. Int Psychogeriatr 2014; 26: 987-94.
55. Wilson AC, Dugger BN, Dickson DW, Wang DS. TDP-43 in aging and Alzheimers disease-a review. Int J Clin Exp Pathol 2011; 4: 147-55.
56. Wilson RS, Yu L, Trojanowski JQ, Chen EY, Boyle PA, Bennett DA, et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol 2013; 70: 1418-24.